For CMS4 CRC, except for KRAS, a representative oncogene employed as a therapeutic target, the kinase CTNNB1 with the second highest WIG may be a potential alternative therapeutic target to CRC, and combinatorial inhibition of KRAS and CTNNB1 may provide a potential combination therapy. Here, CTNNB1 is linked to colorectal carcinoma.